Role of anthracyclines in the era of targeted therapy

被引:228
作者
Cortes-Funes, Hernan [1 ]
Coronado, Cyntia [1 ]
机构
[1] Hosp Univ 12 Octubre, Div Med Oncol, E-28041 Madrid, Spain
关键词
doxorubicin; epirubicin; daunorubicin; taxanes; trastuzumab; cardiomyopathy; review; METASTATIC BREAST-CANCER; PEGYLATED-LIPOSOMAL DOXORUBICIN; RANDOMIZED PHASE-III; KAPOSIS-SARCOMA; TOPOISOMERASE-II; CHEMOTHERAPY; CARDIOTOXICITY; PACLITAXEL; TRIAL; TRASTUZUMAB;
D O I
10.1007/s12012-007-0015-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anthracyclines such as doxorubicin, epirubicin, and daunorubicin are among the most active cytoxic agents for treatment of a wide variety of solid tumors and hematological malignancies. The downside associated with chronic administration of anthracyclines is the induction of cardiomyopathy and congestive heart failure, usually refractory to common treatments. Anthracycline liposomal formulations are currently the best-known alternatives to improve the index and spectrum of anticancer activity of these drugs and decrease their cardiotoxicity. In the current target therapy era in oncology, anthracyclines increase the antitumor effects in more than additive fashion, being excellent partners for other active agents like taxanes and trastuzumab. It is important to note, however, that the enhanced antitumor activity of these combination therapies is often accompanied with increased cardiotoxicity. The issue of anthracycline cardiotoxicity has not been solved so far and it is also important to stress the current lack of proper prevention and treatment strategies.
引用
收藏
页码:56 / 60
页数:5
相关论文
共 32 条
[1]  
BONADONNA G, 1975, Cancer Chemotherapy Reports Part 3, V6, P381
[2]   Topoisomerase IIα gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer [J].
Buzdar, Aman J. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2409-2411
[3]  
Cheung TW, 1999, CLIN CANCER RES, V5, P3432
[4]   A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993) [J].
Coleman, RE ;
Biganzoli, L ;
Canney, P ;
Dirix, L ;
Mauriac, L ;
Chollet, P ;
Batter, V ;
Ngalula-Kabanga, E ;
Dittrich, C ;
Piccart, M .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (07) :882-887
[5]  
CVTOVIC RC, 2005, DRUGS, V65, P1005
[6]  
DEVITA VT, 2003, DRUG DEV PRINCIPLES, P354
[7]  
DOROSHOW J, 2001, CANC CHEMOTHERAPHY B, V13, P500
[8]   Pathogenesis of cardiotoxicity induced by anthracyclines [J].
Elliott, Perry .
SEMINARS IN ONCOLOGY, 2006, 33 (03) :S2-S7
[9]  
Feldman AM, 2000, CIRCULATION, V102, P272
[10]   ANTHRACYCLINE RESISTANCE [J].
FRICHE, E ;
SKOVSGAARD, T ;
NISSEN, NI .
ACTA ONCOLOGICA, 1989, 28 (06) :877-881